Abstract:S100β and neuron-specific enolase (NSE) are brain injury biomarkers, mainly used in brain trauma, cerebral stroke and hypoxic ischemia encephalopathy. The aim of this study was to study the clinical significance of serum S100β and NSE in diagnosing sepsis-associated encephalopathy (SAE) and predicting its prognosis. This was a prospective and observational study. Clinical data of septic patients were collected within 24 h after ICU admission from May 2012 to April 2013. We evaluated the level of consciousness twice per day. SAE was defined as cerebral dysfunction in the presence of sepsis that fulfilled the exclusion criteria. The infection biochemical indicators, Glasgow coma scale (GCS) score, acute physiology and chronic health evaluation score II, serum NSE and S100β were newly measured or evaluated for SAE patients. Finally, hospital mortality, bacteriological categories, length of ICU stay and length of hospital stay were also recorded for all enrolled patients. The data was analyzed with the Chi square test, two-sample t test or Mann–Whitney U test between two groups. The correlation between two factors was analyzed using the Pearson or Spearman analysis. Receiver operating characteristic (ROC) curves were used to determine the ability of S100β and NSE in diagnosing SAE and predicting the hospital mortality. In addition, cut-off points were obtained from the curves to determine the highest sum of sensitivity and specificity. Of 112 enrolled patients, 48 patients were diagnosed with SAE. The serum S100β and NSE concentrations in SAE patients were both significantly higher than in non-SAE patients 0.306 (IQR 0.157–0.880) μg/L vs. 0.095 (IQR 0.066–0.177) μg/L, 24.87 (IQR 31.73–12.73) ng/mL vs. 15.49 (IQR 9.88–21.46) ng/mL, P < 0.01]. GCS scores were related more closely to S100β than NSE (−0.595 vs. −0.337). S100β levels of 0.131 μg/L diagnosed SAE with 67.2 % specificity and 85.4 % sensitivity in the ROC curve, the area under the curve was 0.824 (95 % confidence interval 0.750–0.898). NSE levels of 24.15 ng/mL diagnosed SAE with 82.8 % specificity and 54.2 % sensitivity, and the area under the curve was 0.664 (95 % confidence interval 0.561–0.767). In addition, the area under the curve for S100β for predicting hospital mortality was larger than for NSE (0.730 vs. 0.590). Serum S100β concentrations in SAE patients were significantly higher than in non-SAE patients. These may be related to the severity of SAE and may predict the outcome of sepsis. The efficacy and sensitivity of serum S100β in diagnosing SAE were high, but it had a low specificity. Moreover, compared to NSE, serum S100β was better for both diagnosing SAE and predicting the outcome of sepsis.

Diagnostic and Prognostic Values of S100B versus Neuron Specific Enolase for Traumatic Brain Injury; a Systematic Review and Meta-analysis

Utility of neuron-specific enolase in traumatic brain injury; relations to S100B levels, outcome, and extracranial injury severity

The Predictive Role of Systemic Inflammation Response Index in the Prognosis of Traumatic Brain Injury: A Propensity Score Matching Study.

S-100B and Neuron Specific Enolase in Outcome Prediction of Severe Head Injury

Serum S100β is a Better Biomarker Than Neuron-Specific Enolase for Sepsis-Associated Encephalopathy and Determining Its Prognosis: A Prospective and Observational Study

Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury

Update on the role of S100B in traumatic brain injury in pediatric population: a meta-analysis

Diagnostic and prognostic value of serum S100B in sepsis-associated encephalopathy: A systematic review and meta-analysis

Post-mortem utility of Neuron Specific Enolase (NSE) and Calcium Binding Protein B (S100B) for differentiating traumatic brain injury from other causes of death

The predictive value of S-100B and NSE in outcome of patients with severe head injury

Serum S-100B for mild traumatic brain injury: a systematic review and meta-analysis of diagnostic test accuracy

Role of Diffusion Tensor Imaging Combined with Neuron-Specific Enolase and S100 Calcium-binding Protein B Detection in Predicting the Prognosis of Moderate and Severe Traumatic Brain Injury

The Prognostic Value of Serum Neuron Specific Enolase (NSE) and S100B Level in Patients of Acute Spinal Cord Injury

Prediction of Neurocognitive Outcome after Moderate-Severe Traumatic Brain Injury Using Serum Neuron-Specific Enolase and S100 biomarkers

Association between Blood and Computed Tomographic Imaging Biomarkers in a Cohort of Mild Traumatic Brain Injury Patients

Comparing Blood Biomarkers to Clinical Decision Rules to Select Patients Suspected of Traumatic Brain Injury for Head Computed Tomography.

Clinical Significance of Neuron Specific Enolase and S100 Beta Protein in Intracranial Infection and Brain Injury.

Clinical Evaluation of Prognosis of Severe Posttraumatic Brain Injuries by Using S-100B

Clinical value of S100B in detecting intracranial injury in elderly patients with mild traumatic brain injury

876 Neuron Specific Enolase and S-100 Protein in Sepsis Associated Encephalopathy (SAE)

Influence of Blood–Brain Barrier Integrity on Brain Protein Biomarker Clearance in Severe Traumatic Brain Injury: A Longitudinal Prospective Study